"tyrosine kinase receptor" trang 9 - tải miễn phí từ tailieuXANH
Case report: Primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

Case report: Primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
4    73    0
Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery

Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery
8    64    0
SoLAT (Sorafenib Lenvatinib alternating treatment): A new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

SoLAT (Sorafenib Lenvatinib alternating treatment): A new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
12    60    0
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study

Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
6    56    0
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: A phase 1 dose-escalation trial

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: A phase 1 dose-escalation trial
7    65    0
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
10    77    0
Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
10    55    0
Validation of an NGS mutation detection panel for melanoma

Validation of an NGS mutation detection panel for melanoma
7    65    0
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: A randomized, placebo-controlled phase II AIO trial with serum biomarker program

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: A randomized, placebo-controlled phase II AIO trial with serum biomarker program
13    43    0
Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: A single-institute analysis

Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: A single-institute analysis
7    48    0
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
8    51    0
Molecular chess? Hallmarks of anti-cancer drug resistance

Molecular chess? Hallmarks of anti-cancer drug resistance
8    66    0
The non-genomic loss of function of tumor suppressors: An essential role in the pathogenesis of chronic myeloid leukemia chronic phase

The non-genomic loss of function of tumor suppressors: An essential role in the pathogenesis of chronic myeloid leukemia chronic phase
8    71    0
Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations

Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations
7    44    0
Pazolimus: Pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis

Pazolimus: Pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
8    97    0
Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer

Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer
5    59    0
Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer

Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer
8    64    0
Cross-talk between the Tissue Factor/ coagulation factor VIIa complex and the tyrosine kinase receptor EphA2 in cancer

Cross-talk between the Tissue Factor/ coagulation factor VIIa complex and the tyrosine kinase receptor EphA2 in cancer
14    48    0
TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines

TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines
18    57    0
Off-label use of targeted therapies in osteosarcomas: Data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)

Off-label use of targeted therapies in osteosarcomas: Data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
9    42    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.